Please login to the form below

Not currently logged in
Email:
Password:

oral octreotide acetate

This page shows the latest oral octreotide acetate news and features for those working in and with pharma, biotech and healthcare.

Roche licenses Chiasma’s acromegaly drug in $595m deal

Roche licenses Chiasma’s acromegaly drug in $595m deal

The licensing deal - valued at up to $595m - is for Octreolin (oral octreotide acetate), a drug candidate which which is currently in phase III testing for acromegaly and also in development ... Our oral octreotide has the potential to improve the

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics